Associate Director, KOL Engagement (Endocrinology)

KOL Engagement Leader, Endocrinology

BridgeBio Pharma is preparing to launch encaleret, the first oral calcium-sensing receptor (CaSR) negative allosteric modulator designed specifically for patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1). This role serves as the primary bridge between BridgeBio and the endocrinology thought leader community ahead of and through the encaleret launch.

• Eastern U.S. Territory: Cultivate long-term, trust-based relationships with academic thought leaders, community endocrinologists, and rare disease specialists who influence ADH1 diagnosis and management. Develop and manage the encaleret speaker bureau, including structure, speaker identification and training, and innovative delivery formats.
• Western U.S. Territory: Cultivate long-term, trust-based relationships with academic thought leaders, community endocrinologists, and rare disease specialists who influence ADH1 diagnosis and management. Develop and manage the encaleret speaker bureau, including structure, speaker identification and training, and innovative delivery formats.

Two positions are available: one covering the Eastern U.S. and one covering the Western U.S. Both are remote-based roles with up to 60% travel.

Qualifications

• 7+ years of pharmaceutical/biotech industry experience in commercial roles (KOL engagement, marketing, sales leadership, or medical affairs)
• Deep familiarity with the endocrinology landscape, including academic medical centers, endocrine professional societies, and relevant disease communities
• Proven ability to design and execute KOL engagement strategies, advisory boards, and speaker bureau programs in a compliant, outcomes-driven manner
• Strong cross-functional collaboration skills; comfortable operating in a matrixed environment across commercial, medical, and access functions
• High-level strategic thinking with the ability to convert field insights into actionable commercial strategy
• Entrepreneurial mindset with a patient-first orientation — rare disease experience in a launch-stage or early commercial environment is strongly valued
• Outstanding communication and presentation skills, both written and verbal
• Prior experience at a rare disease or specialty biotech company during product launch
• Experience in hypoparathyroidism, ADH1, or calcium/phosphate metabolic disorders
• Familiarity with CaSR biology, genetic endocrine disease, or rare endocrine disorder management

Preferred Qualifications

• Experience in hypoparathyroidism, ADH1, or calcium/phosphate metabolic disorders
• Familiarity with CaSR biology, genetic endocrine disease, or rare endocrine disorder management
• Prior experience at a rare disease or specialty biotech company during product launch